Table 1 Patient characteristics (n = 1140)
Characteristic | n (%) or mean ± SD |
|---|---|
Age at diagnosis, years | 46.0 ± 14.1 |
Age at recruitment, years | 57.4 ± 12.3 |
Follow-up duration, years | 3.4 ± 1.7 |
Sex | |
 Male | 148 (13.0 %) |
 Female | 992 (87.2 %) |
Race | |
 White | 1012 (93.3 %) |
 Asian | 50 (4.7 %) |
 Australian Aboriginal or Torres Strait Islander | 14 (1.3 %) |
 Other | 9 (0.9 %) |
Disease duration at recruitmenta | 11.3 ± 9.9 |
  ≤ 2 years | 163 (14.3 %) |
  ≤ 5 years | 356 (31.2 %) |
Disease subtypeb | |
 Diffuse | 310 (27.2 %) |
 Limited | 830 (72.8 %) |
Overlap disease features present everc | 267 (23.4Â %) |
 Rheumatoid arthritis | 22 (1.9 %) |
 Polymyositis | 6 (0.5 %) |
 Dermatomyositis | 1 (0.01 %) |
 Sjögren’s syndrome | 21 (1.8 %) |
 SLE | 9 (0.8 %) |
Serological profile at recruitment | |
 Anti-centromere ANA | 517 (46.2 %) |
 Anti-Scl-70 antibodies | 167 (15.2 %) |
 Anti-RNAP antibodies | 84 (13.3 %) |
 Anti-U1 RNP antibodies | 22 (2.0 %) |
 Anti-Ro antibodies | 72 (6.6 %) |
 Anti-La antibodies | 18 (1.6 %) |
 Anti-Sm antibodies | 6 (0.6 %) |
 Anti-PM-Scl antibodies | 15 (1.4 %) |
 Anti-dsDNA antibodies | 26 (3.1 %) |
 Anti-Jo-1 antibodies | 5 (0.5 %) |
 ANCA | 134 (12.9 %) |
  MPO specificity | 17 (1.6 %) |
  PR-3 specificity | 22 (2.1 %) |
 Rheumatoid factor | 288 (27.2 %) |
 Anti-phospholipid antibodies | 272 (25.7 %) |
  Cardiolipin IgM | 165 (65.0 %) |
  Cardiolipin IgG | 105 (39.3 %) |
 Anti-β2-glycoprotein antibody | 84 (33.0 %) |
 Lupus anticoagulant | 26 (3.1 %) |